"p73 is a transcription factor of the p53 tumor suppressor family. In approximately 50% of all cancer patientsthe tumor suppressor function of p53 is irreversibly disabled by point mutations, which makes p53 one of themost frequently mutated genes in cancer. This is entirely different for p73 and much of my previous work inthis field has been devoted to research on the role of p73 in cancer.In sharp contrast to p53, p73 is often highly expressed in its wild-type form in solid tumors compared tothe surrounding normal tissue. This suggests the rather challenging hypothesis that p73 has oncogenicfunctions in cancer cells, which promote tumor progression and therapy resistance. This concept is supportedby clinical data demonstrating p73 overexpression to be correlated with advanced tumor stage, metastasis,therapy resistance and poor overall survival in multiple tumor entities including the ‘major killers’: breast,lung and colorectal cancer. When p73 is depleted from cancer cell lines, tumor cell proliferation andtumorigenicity are reduced, indicating that tumor cells with high p73 expression are p73-dependent. Thisplaces p73 in line with oncogenes like Myc or mutant Ras, which are similarly essential for the tumorigenicphenotype. However, tumor cells are not only addicted to a particular oncogene but in many cases codependenton other cellular factors - a phenomenon termed ‘non-oncogene addiction’. Since p73 also hastumor suppressive functions, p73-dependent tumor cells are likely to be critically dependent on cooperatingfactors, which keep the proapoptotic and tumor suppressive functions of p73 in check. Inhibition of thesefactors would be ‘synthetically lethal’ with overexpression of p73. From a clinical point-of-view it would beextremely valuable, if we knew these factors and were able to block them in order to reactivate p73’s tumorsuppressor activity and trigger growth inhibition or cell death. This approach promises to be specificallyeffective in the therapeutically challenging p73-dependent tumors with little or no side effects in normaltissues with low p73 expression.The goal of this project is therefore the identification and validation of such synthetic lethal interactionswith p73 using different functional genomics approaches. In the first part of the project we will characterizethe impact of p73-dependence on gene expression using genome-wide expression and global chromatin stateprofiling. This will enhance our molecular understanding why cancer cells rely on high-level expression ofp73. In addition, this will pinpoint genes and pathways, which are co-expressed and activated together withp73 and which are therefore candidate genes for therapeutic targeting of p73-dependent cancer cells. In thesecond part of the project we will use RNAi screening techniques on a genome-wide scale to identify in anunbiased manner cellular factors, which enable cancer cells to tolerate high-level expression of p73. Thesegenes are essential for long-term proliferation and survival in the context of p73 overexpression and could beideal drug targets for a tumor-selective therapy of the prognostically dismal class of p73-dependent tumors"